Evidence map›Paper›PMID 34075385›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Unified platform for genetic and serological detection of COVID-19 with single-molecule technology.

Noa Furth, Shay Shilo, Niv Cohen, Nir Erez, Vadim Fedyuk, Alexander M Schrager, Adina Weinberger, Amiel A Dror, Asaf Zigron, Mona Shehadeh and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Noa Furth *Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Shay Shilo *Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Niv Cohen *Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Nir ErezDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Vadim FedyukDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Alexander M SchragerHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Adina WeinbergerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Amiel A DrorDepartment of Otolaryngology, Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel.
Asaf ZigronOral and Maxillofacial Department, Galilee Medical Center, Nahariya, Israel.
Mona ShehadehClinical Laboratories division, Clinical Biochemistry and Endocrinology laboratory, Galilee Medical Center, Naharia, Israel.
Eyal SelaDepartment of Otolaryngology, Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel.
Samer SroujiOral and Maxillofacial Department, Galilee Medical Center, Nahariya, Israel.
Sharon AmitSheba Medical Center, Ramat Gan, Israel.
Itzchak LevySheba Medical Center, Ramat Gan, Israel.
Eran SegalDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Rony DahanDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Dan JonesSeqLL, Woburn, MA, USA.
Daniel C DouekHuman Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
Efrat ShemaDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Weizmann Institute of Science · ILBar-Ilan University · ILNational Institutes of Health · USSheba Medical Center · ILTel Aviv University · IL

Funding

Host Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9M
The Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9M
T Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4M
The HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5M
Innate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8M
InflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9M
6 · The paper itself

Abstract

The COVID-19 pandemic raises the need for diverse diagnostic approaches to rapidly detect different stages of viral infection. The flexible and quantitative nature of single-molecule imaging technology renders it optimal for development of new diagnostic tools. Here we present a proof-of-concept for a single-molecule based, enzyme-free assay for detection of SARS-CoV-2. The unified platform we developed allows direct detection of the viral genetic material from patients' samples, as well as their immune response consisting of IgG and IgM antibodies. Thus, it establishes a platform for diagnostics of COVID-19, which could also be adjusted to diagnose additional pathogens.

Identifiers

PMID34075385
PMCPMC8168389
OpenAlexW3164719581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.